Korro Bio (NASDAQ:KRRO) Upgraded at Cantor Fitzgerald

Korro Bio (NASDAQ:KRRO - Get Free Report) was upgraded by stock analysts at Cantor Fitzgerald to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

KRRO has been the topic of a number of other reports. HC Wainwright reaffirmed a "buy" rating and set a $115.00 price objective on shares of Korro Bio in a research report on Thursday, March 20th. Oppenheimer started coverage on shares of Korro Bio in a report on Friday, January 10th. They set an "outperform" rating and a $155.00 price target on the stock. Chardan Capital started coverage on Korro Bio in a report on Wednesday, April 16th. They set a "buy" rating and a $25.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 19th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $114.63.

Korro Bio Stock Down 4.6 %

Shares of NASDAQ:KRRO opened at $16.67 on Tuesday. The company's fifty day moving average is $19.07 and its two-hundred day moving average is $37.06. The company has a market cap of $156.51 million, a P/E ratio of -1.78 and a beta of 2.31. Korro Bio has a 12-month low of $11.13 and a 12-month high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter. Equities research analysts anticipate that Korro Bio will post -9.52 earnings per share for the current year.

Hedge Funds Weigh In On Korro Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. bought a new stake in shares of Korro Bio during the 4th quarter worth $26,870,000. Driehaus Capital Management LLC lifted its position in Korro Bio by 220.3% during the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company's stock worth $18,841,000 after acquiring an additional 340,410 shares during the last quarter. Woodline Partners LP bought a new stake in Korro Bio during the fourth quarter valued at about $3,887,000. Franklin Resources Inc. acquired a new stake in shares of Korro Bio in the fourth quarter valued at about $3,493,000. Finally, Tri Locum Partners LP increased its stake in shares of Korro Bio by 125.3% in the fourth quarter. Tri Locum Partners LP now owns 144,216 shares of the company's stock worth $5,490,000 after purchasing an additional 80,202 shares during the period. Institutional investors and hedge funds own 13.18% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.